- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05052502
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand (COMBAT)
Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Thailand currently has a well-developed and robust surveillance system based on detailed mapping of all cases to the village foci level and stratification of response. In fiscal year 2019, 5,833 cases of malaria were reported with 83.0% P. vivax and 12.9% P. falciparum; nine deaths were reported. This represents a 20.8% decrease in total cases from fiscal year 2018. Currently, there are 701 "A1" villages in 44 provinces.
The research proposed here will evaluate the effectiveness and feasibility of enhanced reactive focal mass drug administration, results of which will have direct implications for continued roll out the community-led foci management, providing practical guidance that other malaria programs can utilize. Responding to the malaria among high risk populations is a requirement from the National Malaria Elimination Strategy in Thailand. Additionally, Thailand has experienced outbreaks related to forest work over the past several years, and consequently the Department of Vector Borne Disease (DVBD) is interested in introducing more aggressive parasite elimination strategies, including rfMDA for P. falciparum and P. vivax specifically targeting high-risk populations to interrupt transmission and rapidly accelerate elimination.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Adam Bennett, MA, PhD
- Numer telefonu: 1-415-476-5590
- E-mail: adam.bennett@ucsf.edu
Lokalizacje studiów
-
-
-
Bangkok, Tajlandia
- Rekrutacyjny
- Division of Vector Born Diseases, Ministry of Health
-
Kontakt:
- Prayuth Sudathip, DrPH
- Numer telefonu: 02-590-3106-7
- E-mail: psudathip@gmail.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria for rfMDA:
- Index cases: Presented as a confirmed malaria case to an intervention health facility or village malaria worker, and lives in a village within a selected intervention subdistrict, or worked or spent at least one night at a forest or forest-fringe site in the past 30 days located within an intervention subdistrict
- Village residents: Lives in a village within a selected intervention subdistrict area and in one of the five households closest to the residence of an index case of malaria
- Co-worker/traveler referral: Worked or traveled and spent at least one night in forest in past 30 days in same location within an intervention subdistrict as an index case of malaria
- All participants: Willing and available to participate in the study and informed consent for participant under the age of 18 will be provided by the parent or guardian. Participants for focus group discussions (FGDs) and key informant interviews (KIIs); 18 years of age or older
Exclusion Criteria:
• For rfMDA:
- Previous participation in the study as a result of any rfMDA event in the past 30 days
- Individuals with severe disease or drug contra-indications will be excluded from the treatment component only
- Artesunate-Mefloquine: Pregnancy in the first trimester, or known drug allergy
- Use of Mefloquine within 60 days of first treatment prior to enrollment date.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Ekranizacja
- Przydział: Randomizowane
- Model interwencyjny: Przypisanie czynnikowe
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: reactive focal mass drug administration (rfMDA)
Reactive FMDA (rfMDA) led by VMVs in response to cases in study area sub-district, in both villages and forest workers; quantitative G6PD testing for all individuals and 14-day PQ for G6PD non-deficient.
|
Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.
Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials. For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants. |
Aktywny komparator: Control
Standard of care including case management through health facilities and malaria posts/VMVs; village-based RACD conducted by district staff in some areas.
|
Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Confirmed P. falciparum and P. vivax malaria parasite incidence
Ramy czasowe: 3 months
|
Defined as the number of outpatient (OPD) malaria confirmed and suspected cases per person per year for each sub-district, as ascertained from the health facility registers, utilizing administrative catchment population size estimates for the exposure denominator.
|
3 months
|
PCR-based P. falciparum and P. vivax parasite prevalence in sampled sub-districts
Ramy czasowe: 3 months
|
Defined as the proportion of individuals ≥18 months old with P. falciparum or P. vivax infection (detected by PCR) out of all individuals ≥18 months tested within the end line survey.
|
3 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Population coverage of rfMDA interventions
Ramy czasowe: 3 months
|
This indicator will be measured in two ways.
Operational program coverage will be defined as the proportion of individuals ≥18 months old and households visited and offered the rfMDA interventions within the target areas per time period.
Effective program coverage is defined as the proportion of individuals (≥18 months old) that agreed to participate in the rfMDA intervention among all individuals ≥18 months old eligible to participate in the intervention in the target population per time period.
|
3 months
|
Feasibility of conducting rfMDA at the community level
Ramy czasowe: 3 months
|
Feasibility will be determined based upon a combination of population coverage data, responses of provincial, district, and health staff, VMWs, and community members to interviews and focus groups at baseline and end line, village malaria workers (VMWs) competency checklists at baseline, midline, and end line, and cost data.
|
3 months
|
Acceptability of rfMDA approach
Ramy czasowe: 3 months
|
Acceptability will be determined based upon refusal rates during interventions and responses of community members and VMWs to end line questionnaire, interviews, and focus groups.
|
3 months
|
Adverse event rate
Ramy czasowe: 3 months
|
Safety measures will include the adverse event rate amongst treated individuals and hemoglobin measurement pre and post treatment for individuals receiving PQ.
|
3 months
|
Operational feasibility of glucose-6-phosphate dehydrogenase (G6PD) testing and referral
Ramy czasowe: 3 months
|
Operational feasibility of G6PD testing and referral will be determined by responses of health staff and VMWs to interviews and focus groups at baseline and end line and competency checklists at baseline, midline, and end line, the proportion of P. vivax cases with a valid G6PD result, and proportion of referred cases presenting at a health facility for G6PD testing.
|
3 months
|
Assessment of P. vivax treatment adherence
Ramy czasowe: 3 months
|
Treatment adherence will be determined by the proportion of P. vivax cases with physical evidence of adherence through pill count and the P. vivax relapse rate across study arms.
|
3 months
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Główny śledczy: Adam Bennett, MA, PhD, University of California, San Francisco
- Główny śledczy: Cheewanan Lertpiriyasuwat, MD, Department of Disease Control, Ministry of Public Health Thailand
Publikacje i pomocne linki
Publikacje ogólne
- Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012 Sep 4;345:e5661. doi: 10.1136/bmj.e5661. No abstract available.
- Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, Simpson JA, Soenarto Y, Anstey NM, Price RN. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Med. 2017 Aug 29;14(8):e1002379. doi: 10.1371/journal.pmed.1002379. eCollection 2017 Aug.
- Guidelines for the Treatment of Malaria. 3rd edition. Geneva: World Health Organization; 2015. Available from http://www.ncbi.nlm.nih.gov/books/NBK294440/
- Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012 Jan;9(1):e1001165. doi: 10.1371/journal.pmed.1001165. Epub 2012 Jan 31.
- Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013 Sep 7;382(9895):900-11. doi: 10.1016/S0140-6736(13)60310-4. Epub 2013 Apr 15. Erratum In: Lancet. 2013 Sep 7;382(9895):858.
- Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, Abeyasinghe RR, Rodriguez MH, Maharaj R, Tanner M, Targett G. Operational strategies to achieve and maintain malaria elimination. Lancet. 2010 Nov 6;376(9752):1592-603. doi: 10.1016/S0140-6736(10)61269-X. Epub 2010 Oct 28.
- Hustedt J, Canavati SE, Rang C, Ashton RA, Khim N, Berne L, Kim S, Sovannaroth S, Ly P, Menard D, Cox J, Meek S, Roca-Feltrer A. Reactive case-detection of malaria in Pailin Province, Western Cambodia: lessons from a year-long evaluation in a pre-elimination setting. Malar J. 2016 Mar 1;15:132. doi: 10.1186/s12936-016-1191-z.
- Rossi G, Van den Bergh R, Nguon C, Debackere M, Vernaeve L, Khim N, Kim S, Menard D, De Smet M, Kindermans JM. Adapting Reactive Case Detection Strategies for falciparum Malaria in a Low-Transmission Area in Cambodia. Clin Infect Dis. 2018 Jan 6;66(2):296-298. doi: 10.1093/cid/cix781.
- Landier J, Parker DM, Thu AM, Lwin KM, Delmas G, Nosten FH; Malaria Elimination Task Force Group. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet. 2018 May 12;391(10133):1916-1926. doi: 10.1016/S0140-6736(18)30792-X. Epub 2018 Apr 24.
- Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, Sakuntabhai A, Satyagraha AW, Williams TN, Baird JK, Hay SI. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013 Nov 15;12:418. doi: 10.1186/1475-2875-12-418.
- White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. Elife. 2014 Nov 18;3:e04692. doi: 10.7554/eLife.04692.
- Center for Malariology Parasitology and Entomology Lao PDR. Lao PDR Malaria National Strategic Plan 2016-2020. (2015).
- WHO. Updated WHO policy recommendation: Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. World Health Organisation (2012).
- Baum E, Sattabongkot J, Sirichaisinthop J, Kiattibutr K, Davies DH, Jain A, Lo E, Lee MC, Randall AZ, Molina DM, Liang X, Cui L, Felgner PL, Yan G. Submicroscopic and asymptomatic Plasmodium falciparum and Plasmodium vivax infections are common in western Thailand - molecular and serological evidence. Malar J. 2015 Feb 25;14:95. doi: 10.1186/s12936-015-0611-9.
- Corran P, Coleman P, Riley E, Drakeley C. Serology: a robust indicator of malaria transmission intensity? Trends Parasitol. 2007 Dec;23(12):575-82. doi: 10.1016/j.pt.2007.08.023. Epub 2007 Nov 7.
- Chan CW, Sakihama N, Tachibana S, Idris ZM, Lum JK, Tanabe K, Kaneko A. Plasmodium vivax and Plasmodium falciparum at the crossroads of exchange among islands in Vanuatu: implications for malaria elimination strategies. PLoS One. 2015 Mar 20;10(3):e0119475. doi: 10.1371/journal.pone.0119475. eCollection 2015.
- Beutler E, Duparc S; G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007 Oct;77(4):779-89.
- Das S, Peck RB, Barney R, Jang IK, Kahn M, Zhu M, Domingo GJ. Performance of an ultra-sensitive Plasmodium falciparum HRP2-based rapid diagnostic test with recombinant HRP2, culture parasites, and archived whole blood samples. Malar J. 2018 Mar 17;17(1):118. doi: 10.1186/s12936-018-2268-7. Erratum In: Malar J. 2019 Feb 4;18(1):33.
- Ministry of Health Lao PDR. The Evaluation of G6PD Rapid Tests and the Use of Primaquine for the Treatment of Plasmodium Vivax Infections in Luangprabang, Savannakhet and Champasak Provinces (Apr-Nov 2015). (2015)
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 19-04062020
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Malaria Plasmodium Falciparum
-
Novartis PharmaceuticalsRekrutacyjnyNieskomplikowana malaria Plasmodium falciparumWybrzeże Kości Słoniowej, Kenia, Ghana, Uganda
-
Medicines for Malaria VentureZakończonyNieskomplikowana malaria Plasmodium falciparumUganda, Benin, Burkina Faso, Kongo, Demokratyczna Republika, Gabon, Mozambik, Wietnam
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesZakończonyNieskomplikowana malaria Plasmodium falciparumTanzania
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical...RekrutacyjnyMalaria, Plasmodium FalciparumGambia
-
PfizerZakończonyMALARIA PLASMODIUM FALCIPARUMIndie
-
SanofiMedicines for Malaria VentureZakończonyZakażenie Plasmodium FalciparumBenin, Burkina Faso, Gabon, Kenia, Uganda
-
Muhimbili University of Health and Allied SciencesUppsala University; The Swedish Research CouncilJeszcze nie rekrutacjaNieskomplikowana malaria Plasmodium falciparumTanzania
-
Novartis PharmaceuticalsEuropean and Developing Countries Clinical Trials Partnership (EDCTP)RekrutacyjnyNieskomplikowana malaria Plasmodium falciparumBurkina Faso, Mali, Gabon
-
David SaundersNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; Royal... i inni współpracownicyZawieszonyNieskomplikowana malaria Plasmodium falciparumKambodża
-
University of OxfordJeszcze nie rekrutacjaNieskomplikowana malaria Plasmodium falciparum
Badania kliniczne na Case Management and Follow-up
-
Milton S. Hershey Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)ZakończonyNadciśnienie | Cukrzyca | HiperlipidemiaStany Zjednoczone
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRekrutacyjnyDemencja | Łagodne upośledzenie funkcji poznawczych | Demencja, mieszana | Demencja typu Alzheimera | Subiektywne upośledzenie funkcji poznawczych | Demencja starczaSzwecja
-
Institut Claudius RegaudZakończony
-
Acibadem UniversityMarmara UniversityZakończonyOtyłość | Zapalenie stawów kolanowych | Powikłania artroplastyki | Saldo; ZniekształconyIndyk
-
Afyonkarahisar Health Sciences UniversityRekrutacyjny
-
University of Rhode IslandStuart Sinoff, MD; Peter J Snyder, MD; BayCare Health SystemRekrutacyjnyZmiana poznawcza | Choroba Alzheimera | Starzenie się | Łagodne upośledzenie funkcji poznawczych | Łagodna demencjaStany Zjednoczone
-
Dr. Faizan AwanZakończonyCovid19 | Stres zawodowyZjednoczone Królestwo
-
Istanbul Medeniyet UniversityNieznany
-
Hacettepe UniversityZakończonyChoroba Parkinsona | Zaburzenia ruchoweIndyk
-
Istanbul University - Cerrahpasa (IUC)Jeszcze nie rekrutacja